This implies that targeting the Gas6/AXL pathway in gliomas might not only have direct effects on tumor proliferation signals but could have secondary effects by decreasing the vascularization of the tumor and may present a good target for glioma therapy. This evidence concerns the gene GAS6 and central nervous system cancer.